i-GETAID

Another key area is postoperative recurrence after ileocolonic anastomosis, with interest in maintaining remission and preventing renewed mucosal injury following intestinal surgery.

• Postoperative recurrence
• Ileocolonic anastomosis
• Mucosal recurrence

Clinical research in this domain centers on patients with early postoperative lesions and the need for sustained control of Crohn’s disease activity.

The sponsor is also involved in ulcerative colitis, with studies examining treat-to-target care, patient education, and home-based monitoring tools to support tighter disease control during biologic treatment.

• Treat-to-target care
• Fecal calprotectin
• Telemonitoring

This area highlights interest in combining patient-reported follow-up with objective inflammatory markers to guide ongoing management in inflammatory bowel disease.

Research also extends to fistulising perianal Crohn’s disease, a complex phenotype marked by active fistula tracts and significant therapeutic challenge within inflammatory bowel disease care.

• Perianal fistula
• Fistulising disease
• Complex Crohn’s phenotype

This focus reflects interest in difficult-to-treat disease manifestations that require specialized clinical attention.

The sponsor’s trial portfolio includes evaluation of biologic therapies used in Crohn’s disease and ulcerative colitis, with attention to agents such as adalimumab, ustekinumab, guselkumab, and mirikizumab.

• Biologic treatment
• Advanced immunotherapy
• Inflammatory bowel disease

These studies place emphasis on therapeutic management across active intestinal inflammation, postoperative disease, and fistulising complications.